INS and diabetes mellitus: Antidiabetic drugs (oral hypoglycemic agents or insulin) represented an expenditure of about €1.1 billion in 2012, i.e., one-half (49%) of all diabetes-specific expenditure (€2.3 billion, see Fig. 2).